NRGN Neurogen (MM)

Neurogen Corporation (NASDAQ: NRGN), a drug development company focused on improved drugs for psychiatric and neurological disorders, today announced financial results for the quarter ended June 30, 2009.

Stephen R. Davis, President and CEO said, "During the second quarter we continued our plan to conserve cash resources while pursuing strategic options. As previously announced, in May we suspended enrollment of new patients in our Parkinson’s disease and Restless Legs Syndrome clinical trials and we have reduced our staff to those necessary to execute the pursuit of a sale of the company or our major assets.”

On a GAAP basis, including non-recurring matters, Neurogen recognized a net loss attributable to common stockholders for the second quarter of 2009 of $7.5 million, or $0.11 per share as compared to a GAAP net loss attributable to common stockholders for the second quarter of 2008 of $11.8 million, or $0.28 per share. On a non-GAAP basis, excluding non-recurring charges relating to restructuring of workforce and the write down of certain assets, net loss for the second quarter of 2009 totaled $3.9 million, or $0.06 per share on 68.7 million weighted shares outstanding as compared to a non-GAAP net loss during the second quarter of 2008 of $8.5 million, or $0.20 per share on 42.1 million weighted average shares outstanding.

Research and development expenses for the second quarter of 2009 decreased to $2.8 million from $8.0 million in the comparable period of 2008. The decrease in R&D expenses for the quarter was due primarily to decreased spending in Neurogen’s clinical and preclinical drug development programs as well as the 2008 and 2009 restructuring of the Company’s workforce.

General and administrative expenses for the second quarter of 2009 increased to $1.2 million from $0.8 million for the comparable period of 2008. The increase for the quarter was due primarily to the effect of a $0.35 million credit recognized in the second quarter of 2009 versus a $0.69 million credit recognized in the second quarter of 2008, in each case related to the cancellation of stock options from employees terminated in Company restructurings.

Neurogen’s cash and marketable securities as of June 30, 2009 totaled $21.9 million. Total liabilities at June 30, 2009 were $11 million.

Non-recurring matters

Asset impairment charges for the second quarter of 2009 were $3.9 million, compared to $7.2 million for the second quarter of 2008. Asset impairment charges in each period were associated with writing down the book value of facilities and equipment associated with previous research and development activities. In the second quarter of 2009, Neurogen recorded a restructuring of workforce charge of $2.4 million, compared to a restructuring of workforce charge in the second quarter of 2008 of $2.6 million. Restructuring of workforce charges in each period relate to the Company’s reductions in staffing levels.

Webcast

Neurogen will host a conference call and webcast to discuss second quarter results at 5:00 p.m. EDT today, August 14, 2009. The webcast will be available in the Investor Relations section of www.neurogen.com and will also be archived there. A replay of the call will be available after 8:00 p.m. EDT on August 14, 2009 and accessible through the close of business, August 21, 2009. To replay the conference call, dial 888-286-8010, or for international callers, 617-801-6888, and use the pass code: 36599619.

About Neurogen

Neurogen Corporation is a drug development company historically focusing on small-molecule drugs to improve the lives of patients suffering from psychiatric and neurological disorders with significant unmet medical need. Neurogen has conducted its drug development independently and, when advantageous, collaborated with world-class pharmaceutical companies to access additional resources and expertise.

Statement Regarding Adjusted (Non-GAAP) Financial Information

In addition to disclosing financial results calculated in accordance with GAAP, the Company has included certain adjusted financial results. Reconciliations between GAAP and adjusted earnings for the three and six months ended June 30, 2009 and 2008 are provided in the table below. The Company believes that the presentation of adjusted results provides meaningful supplemental information regarding our financial results for the three and six months ended June 30, 2009 as compared to the three and six months ended June 30, 2008 because the adjustments between GAAP and adjusted earnings provide information related to the ongoing operations of the Company. The Company believes that this financial information is useful to management and investors in assessing our historical performance and results. The Company will use these adjusted financial measures when evaluating its financial results, as well as for internal planning and forecasting purposes. The adjusted financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated. The adjusted financial measures used by the Company may be calculated differently from and therefore may not be comparable to similarly titled measures used by other companies.

Our results under GAAP have been adjusted for the following events that occurred during the three and six months ended June 30, 2009 and 2008: (1) restructuring of the Company’s workforce that resulted in additional expense in each period, (2) asset impairment charges associated with writing down the value of certain of our facilities and certain related equipment associated with discontinued research and development activities, and (3) the sale of certain non-core patent estates. See the table below for a detailed reconciliation of GAAP and adjusted earnings.

Reconciliations between GAAP and Non-GAAP earnings for the three and six months ended June 30, 2009 and 2008 are provided in the following table:

  Three Months Ended   Three Months Ended   Six Months Ended   Six Months Ended June 30, 2009 June 30, 2008 June 30, 2009 June 30, 2008 [in thousands except per share amounts] (unaudited) Net loss attributable to common stockholders (GAAP) $(7,511) $(11,841) $(18,347) $(28,359) Sale of patent estate (2,650) - (2,650) - Restructuring of workforce 2,355 2,640 2,677 5,130 Asset impairment charges 3,930 7,200 9,176 7,200 Gain on warrants to purchase common stock - (11,954) - (11,954) Deemed preferred dividends -   5,407   -   5,407 Adjusted net loss (Non- GAAP) (3,876)   (8,548)   (9,144)   (22,576) Basic and diluted loss per share attributable to common stockholders (GAAP) $(0.11)   $(0.28)   $(0.27)   $(0.67) Basic and diluted loss per share (Non-GAAP) $(0.06)   $(0.20)   $(0.13)   $(0.54) Shares used in calc of loss per share: Basic and Diluted 68,671   42,131   68,490   42,062

Safe Harbor Statement

The information in this press release contains certain forward-looking statements, made pursuant to applicable securities laws that involve risks and uncertainties as detailed from time to time in Neurogen's SEC filings, including its most recent 10-K. The words “believe”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “may”, “will” and other similar expressions generally identify forward-looking statements. Such forward-looking statements relate to events or developments that we expect or anticipate will occur in the future and include, but are not limited to, statements that are not historical facts relating to the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. Actual results may differ materially from such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of Neurogen’s drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of the Company's drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, Neurogen’s ability to retain key employees for the plans described above, sufficiency of cash to complete the plans described above, Neurogen’s ability to continue as a going concern, Neurogen’s ability to complete a sale of all or substantially all of its assets or enter into any strategic alternative and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Neurogen disclaims any intent and does not assume any obligation to update these forward-looking statements, other than as may be required under applicable law.

  NEUROGEN CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except per share data) (unaudited)         Three Months ended

June 30, 2009

Three Months ended

June 30, 2008

Six Months

ended

June 30, 2009

Six Months

ended

June 30, 2008

  Operating revenues: Sale of patent estate $2,650 $- $2,650 $- Total operating revenues 2,650 2,650   Operating expenses: Research and development 2,776 7,995 6,051 20,049 General and administrative 1,203 756 3,314 2,919 Asset impairment charges 3,930 7,200 9,176 7,200 Restructuring of workforce 2,355 2,640 2,677 5,130 Total operating expenses 10,264 18,591 21,218 35,298 Operating loss (7,614) (18,591) (18,568) (35,298)   Gain on warrants to purchase common stock - 11,954 - 11,954 Other income, net 86 180 176 346 Total other income, net 86 12,134 176 12,300 Tax benefit 17 23 45 46 Net loss (7,511) (6,434) (18,347) (22,952) Deemed preferred dividends - (5,407) - (5,407) Net loss attributable to common stockholders $(7,511) $(11,841) $(18,347) $(28,359)   Basic and diluted loss per share attributable to common stockholders $(0.11) $(0.28) $(0.27) $(0.67) Shares used in calculation of loss per share attributable to common stockholders: Basic and diluted 68,671 42,131 68,490 42,062   NEUROGEN CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) (unaudited)         June 30, 2009   December 31, 2008 Assets Current Assets: Cash and cash equivalents $21,937 $24,106 Marketable securities - 6,967 Total cash and marketable securities 21,937 31,073 Receivables from corporate partners 33 61 Assets held for sale 2,802 5,108 Other current assets, net 939 1,394 Total current assets 25,711 37,636 Restricted cash 121 - Net property, plant and equipment 13 7,102 Other assets, net 22 30 Total assets $25,867 $44,768   Liabilities and Stockholders’ Equity Current liabilities: Accounts payable and accrued expenses $4,085 $4,555 Current portion of loans payable 4,122 4,692 Total current liabilities 8,207 9,247 Long term liabilities: Tenant Security Deposit 121 Loans payable, net of current portion 2,630 2,807 Total liabilities 10,958 12,054 Total stockholders’ equity 14,909 32,714 Total liabilities and stockholders’ equity $25,867 $44,768